2023-504916-14-00
已完成
1 期
An open-label, single-dose phase 1 study to evaluate the Absorption, Metabolism, and Excretion of [14C]-AZ-3102 in Healthy Male Subjects
Azafaros B.V.1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2023年6月21日最近更新:
概览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Azafaros B.V.
- 入组人数
- 7
- 试验地点
- 1
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Christian Freitag
Scientific
Azafaros B.V.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Study of CM383 in Healthy SubjectsNCT07292688Keymed Biosciences Co.Ltd30
已完成
1 期
A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers2024-515124-36-00Integrative Research Laboratories Sweden AB12
尚未招募
1 期
A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PET2024-520078-36-00Alzeca Biosciences Inc.18
尚未招募
1 期
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.2025-524217-89-00Vianex S.A.44
已完成
1 期
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-242024-510774-24-00Adamed Pharma S.A.30